Formulation Development
Quotient Therapeutics Announces Collaboration With Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known…
Karyopharm’s Phase 3 in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
Karyopharm Therapeutics Inc. recently reported topline results from its Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with…
ImmuneBridge Announces New Partnership Focus, Investment & CEO
ImmuneBridge recently announced it will make its platform available to partners – ranging from small biotech startups to established pharmaceutical companies. Therapeutic co-development partners will…
Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell
Nanexa AB recently announced highly promising new results from its long‑acting semaglutide program, developed using the company’s proprietary PharmaShell drug delivery platform. Building on the…
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
Basecamp Research recently announced the launch of the Trillion Gene Atlas, a landmark scientific initiative to generate and model biological data at the trillion-gene scale.…
One-carbon Therapeutics Signs Strategic Collaboration With Tempus to Advance Molecular Insights & Enable Precision Oncology Development of TH9619
One-carbon Therapeutics recently announced a strategic collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine.…
Green Light for First-in-Human Trial of KMCAR T-cell Therapy in Multiple Myeloma
HaemaLogiX Ltd and Peter MacCallum Cancer Centre (Peter Mac) are delighted to announce the achievement of a landmark regulatory milestone: receipt of Clinical Trial Approval…
Lonza & Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO
-Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO (betibeglogene autotemcel), the only FDA-approved gene therapy for…
Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections
Centauri Therapeutics Limited recently announced the its lead clinical candidate in the ABX-01 program, CTX-187, has received Qualified Infectious Disease Product (QIDP) designation from the…
WHITE PAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development
This article explores how AI-driven predictive insights reduce uncertainty in early oral drug development, enabling smarter decisions on solubility, dosing, stability, and scale-up while preserving API, accelerating timelines, and de-risking clinical success .
Medicus Pharma Reports Positive Phase 2 Topline Data Observing 73% Clinical Clearance & 40% Histological Clearance
Medicus Pharma Ltd. recently announced topline results from its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively…
Codexis Signs Agreement to Manufacture 50 g siRNA Using its ECO Synthesis Manufacturing Platform
Codexis, Inc. recently announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using…
FUJIFILM Biotechnologies Unveils ShunzymeX Precision Purification Technology
FUJIFILM Biotechnologies recently unveiled ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics. The technology will be presented this week at the Festival…
BioDuro & Cenra Launch Joint Venture to Expand Resilient Global API Manufacturing Capacity
BioDuro recently announced it has established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB),…
NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben
NorthSea Therapeutics B.V. recently announced the US FDA and the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) have granted Orphan Drug Designations…
ESTEVE CDMO Commences $15.5 Million Expansion of Chicago Small Molecule API Facility
ESTEVE CDMO recently announced it had commenced a $15.5-million investment to enhance production capabilities and associated space at its newly acquired North American facility in…
WHITE PAPER - Small Molecules: Choosing the Right Development Path
This white paper outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
Bioxytran Reports Positive Study Results for a Broad-Range Antiviral Drug in Mild-to-Moderate COVID-19
Bioxytran, Inc. recently announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused…
Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
Quotient Sciences recently announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an…
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Neurizon Therapeutics Limited recently announced the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon’s lead candidate, NUZ-001,…
